首页> 美国卫生研究院文献>Journal of Cellular and Molecular Medicine >Suppressive effect of epigallocatechin‐3‐O‐gallate on endoglin molecular regulation in myocardial fibrosis in vitro and in vivo
【2h】

Suppressive effect of epigallocatechin‐3‐O‐gallate on endoglin molecular regulation in myocardial fibrosis in vitro and in vivo

机译:表没食子儿茶素-3-O-没食子酸酯在体内外对心肌纤维化中内皮糖蛋白分子调控的抑制作用

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。
获取外文期刊封面目录资料

摘要

Epigallocatechin‐3‐O‐gallate (EGCG), derived from green tea, has been studied extensively because of its diverse physiological and pharmacological properties. This study evaluates the protective effect of EGCG on angiotensin II (Ang II)‐induced endoglin expression in vitro and in vivo. Cardiac fibroblasts (CFs) from the thoracic aorta of adult Wistar rats were cultured and induced with Ang II. Western blotting, Northern blotting, real‐time PCR and promoter activity assay were performed. Ang II increased endoglin expression significantly as compared with control cells. The specific extracellular signal‐regulated kinase inhibitor SP600125 (JNK inhibitor), EGCG (100 μM) and c‐Jun N‐terminal kinase (JNK) siRNA attenuated endoglin proteins following Ang II induction. In addition, pre‐treated Ang II‐induced endoglin with EGCG diminished the binding activity of style="fixed-case">AP‐1 by electrophoretic mobility shift assay. Moreover, the luciferase assay results revealed that style="fixed-case">EGCG suppressed the endoglin promoter activity in Ang style="fixed-case">II‐induced style="fixed-case">CFs by style="fixed-case">AP‐1 binding. Finally, style="fixed-case">EGCG and the style="fixed-case">JNK inhibitor ( style="fixed-case">SP600125) were found to have attenuated endoglin expression significantly in Ang style="fixed-case">II‐induced style="fixed-case">CFs, as determined through confocal microscopy. Following in vivo acute myocardial infarction ( style="fixed-case">AMI)‐related myocardial fibrosis study, as well as immunohistochemical and confocal analyses, after treatment with endoglin si style="fixed-case">RNA and style="fixed-case">EGCG (50 mg/kg), the area of myocardial fibrosis reduced by 53.4% and 64.5% and attenuated the left ventricular end‐diastolic and systolic dimensions, and friction shortening in hemodynamic monitor. In conclusion, epigallocatechin‐3‐O‐gallate ( style="fixed-case">EGCG) attenuated the endoglin expression and myocardial fibrosis by anti‐inflammatory effect in vitro and in vivo, the novel suppressive effect was mediated through style="fixed-case">JNK/ style="fixed-case">AP‐1 pathway.
机译:衍生自绿茶的表没食子儿茶素-3-O-没食子酸酯(EGCG)由于其多种生理和药理特性而得到了广泛的研究。这项研究评估了EGCG在体外和体内对血管紧张素II(Ang II)诱导的内皮糖蛋白表达的保护作用。培养成年Wistar大鼠胸主动脉的成纤维细胞(CFs),并用Ang II诱导。进行了Western印迹,Northern印迹,实时PCR和启动子活性测定。与对照细胞相比,Ang II显着增加内皮糖蛋白表达。 Ang II诱导后,特定的细胞外信号调节激酶抑制剂SP600125(JNK抑制剂),EGCG(100μM)和c-Jun N-末端激酶(JNK)siRNA减弱了内皮糖蛋白。此外,通过电泳迁移率变动分析,用EGCG预处理的Ang II诱导的内皮糖蛋白可降低 style =“ fixed-case”> AP -1的结合活性。此外,荧光素酶测定结果显示 style =“ fixed-case”> EGCG 以Ang style =“ fixed-case”> II -诱导的 style抑制了内皮糖蛋白启动子活性。 =“ fixed-case”> CF s通过 style =“ fixed-case”> AP -1绑定。最后,使用 style =“ fixed-case”> EGCG 和 style =“ fixed-case”> JNK 抑制剂( style =“ fixed-case”> SP 600125)被发现在Ang style =“ fixed-case”> II -诱导的 style =“ fixed-case”> CF s中显着减弱了内皮糖蛋白表达,共聚焦显微镜。在使用内皮糖蛋白si style =“ fixed-case治疗后,进行了体内急性心肌梗死( style =” fixed-case“> AMI )相关的心肌纤维化研究以及免疫组化和共聚焦分析“> RNA 和 style =” fixed-case“> EGCG (50 mg / kg),心肌纤维化面积分别减少了53.4%和64.5%,并使左心室舒张末期减弱和收缩期尺寸,以及血流动力学监测仪中的摩擦缩短。总之,Epigallocatechin-3-O-gallate( style =“ fixed-case”> EGCG )通过体内和体外的抗炎作用减弱了内皮糖蛋白的表达和心肌纤维化,其新颖的抑制作用是通过 style =“ fixed-case”> JNK / style =“ fixed-case”> AP -1途径介导。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号